Valuation: GlaxoSmithKline Pharmaceuticals Limited

Market Cap 45TCr 478.49Cr 432.7Cr 399.41Cr 361.53Cr 682.21Cr 702.67Cr 4.79TCr 1.91TCr 24TCr 1.8TCr 1.76TCr 77TCr P/E 2027 *
38.3x
P/E 2028 * 33.5x
Enterprise Value 45TCr 478.49Cr 432.7Cr 399.41Cr 361.53Cr 682.21Cr 702.67Cr 4.79TCr 1.91TCr 24TCr 1.8TCr 1.76TCr 77TCr EV / Sales 2027 *
10.4x
EV / Sales 2028 * 9.28x
Free-Float
24.34%
Yield 2027 *
1.11%
Yield 2028 * 1.11%
04/11 GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026 CI
03/11 GlaxoSmithKline Pharmaceuticals Limited Announces Appointment of Sandeep Seth as Head - Ethics & Compliance, Effective November 3, 2026 CI
03/08 GSK India first-quarter profit rises on steady vaccine demand RE
03/08 GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
03/08 Glaxosmithkline Pharmaceuticals Limited Announces Management Changes CI
29/05 GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Dr. Simrat Sohal from Compliance Officer and Ceases to Be the Senior Management Personnel, Effective August 5, 2026 CI
13/05 GlaxoSmithKline Pharmaceuticals Clocks Higher Fiscal Q4 Consolidated Net Profit MT
13/05 GlaxoSmithKline Pharmaceuticals March-quarter consol profit 2.78 billion rupees RE
13/05 GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2026 CI
13/05 GlaxoSmithKline Pharmaceuticals Limited announces Annual dividend, payable on July 30, 2026 CI
21/04 Glaxosmithkline Pharmaceuticals Limited Announces Appointment of Vinay Subramanian as Commercial Head ? Oncology and Senior Management Personnel, Effective April 20, 2026 CI
31/03 GlaxoSmithKline Pharmaceuticals receives TDS demand liability of 20.1 million rupees RE
24/03 GlaxoSmithKline Pharmaceuticals Ltd receives final order with tax demand liability of 232.1 mln rupees for AY 2023-24 RE

Last Transcript: GlaxoSmithKline Pharmaceuticals Limited

1 day+0.35%
1 week+5.53%
Current month+7.29%
1 month+5.15%
3 months-0.01%
6 months+10.70%
Current year+7.83%
1 week 2,510.9
Extreme 2510.9
2,770
1 month 2,342.7
Extreme 2342.7
2,770
Current year 2,088
Extreme 2088
3,121.1
1 year 2,088
Extreme 2088
3,121.1
3 years 1,472.65
Extreme 1472.65
3,515.95
5 years 1,228
Extreme 1228
3,515.95
10 years 1,020
Extreme 1020
3,515.95
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2022
Director of Finance/CFO - 01/04/2026
Chief Operating Officer - 01/01/2025
Director TitleAgeSince
Chairman 73 01/04/2019
Director/Board Member 59 18/05/2020
Director/Board Member 67 16/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%+5.53%+6.86%+81.23% 478.49Cr
-0.70%+4.58%+40.23%+138.79% 1,27100Cr
+1.11%+4.11%+45.85%+92.54% 68TCr
-0.18%+2.15%+26.25%+112.46% 52TCr
-0.27%+3.72%+39.63%+69.55% 39TCr
-0.16%+0.01%+60.69%+44.94% 36TCr
+0.19%+0.96%+27.07%+58.78% 30TCr
+0.43%+0.23%+3.47%+36.24% 29TCr
-0.22%+1.47%+38.89%+74.73% 25TCr
-1.05%+0.23%+36.10%+121.22% 21TCr
Average -0.05%+2.18%+32.50%+83.05% 43TCr
Weighted average by Cap. -0.11%+2.68%+37.40%+96.76%

Financials

2027 *2028 *
Net sales 4.33TCr 46Cr 42Cr 38Cr 35Cr 66Cr 68Cr 461.85Cr 183.54Cr 2.32TCr 173.01Cr 169.32Cr 7.37TCr 4.85TCr 52Cr 47Cr 43Cr 39Cr 74Cr 76Cr 516.57Cr 205.28Cr 2.59TCr 193.5Cr 189.38Cr 8.25TCr
Net income 1.18TCr 13Cr 11Cr 11Cr 9.52Cr 18Cr 19Cr 126.29Cr 50Cr 633.48Cr 47Cr 46Cr 2.02TCr 1.34TCr 14Cr 13Cr 12Cr 11Cr 20Cr 21Cr 142.89Cr 57Cr 716.76Cr 54Cr 52Cr 2.28TCr
Net Debt - -
Projected Income Statement - Annual - GlaxoSmithKline Pharmaceuticals Limited
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
13/26/13 ₹2,664.50 +0.35% 4,096
12/26/12 ₹2,655.30 -2.61% 4,104
11/26/11 ₹2,726.40 +0.57% 9,488
09/26/09 ₹2,710.85 +6.77% 35,096
08/26/08 ₹2,538.95 +0.56% 2,376
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - GlaxoSmithKline Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,655.30INR
Average target price
3,053.50INR
Spread / Average Target
+15.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GlaxoSmithKline Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. GLAXO Stock